Every Form 4 that Eledon Pharmaceuticals Inc (ELDN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ELDN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ELDN filings page.
Eledon Pharmaceuticals, Inc. reports that Chief Executive Officer David-Alexandre C Gros received 354,454 shares of common stock on 2026-07-31 as settlement of a retention bonus award under an agreement entered into on 2023-04-27. On the same date, 194,791 shares were withheld at $3.38 per share to satisfy tax withholding obligations related to this settlement, resulting in a mix of stock compensation and tax-withholding dispositions.
Eledon Pharmaceuticals, Inc. reported that President Steven Perrin received 152,353 shares of Common Stock on 2026-07-31 upon settlement of a retention bonus award, under an agreement entered into on April 27, 2023. On the same date, 72,138 shares were withheld at $3.38 per share to satisfy tax withholding obligations.
Eledon Pharmaceuticals director John McBride reported the vesting and settlement of restricted stock units into common shares. On January 10, 2026, 3,430 restricted stock units were converted into 3,430 shares of Eledon Pharmaceuticals common stock at a price of $0 per share. These RSUs had been granted on January 10, 2025 and vested 100% one year later. Following this transaction, McBride directly holds 3,430 shares of common stock.
Eledon Pharmaceuticals director Jan Hillson reported the vesting and settlement of 3,430 restricted stock units into 3,430 shares of common stock. The transaction occurred on January 10, 2026 through an option exercise coded "M" at a price of $0 per share. The RSUs were originally granted on January 10, 2025 and vested in full one year later, delivering common shares to the director on a one-for-one basis. Following this transaction, Hillson directly holds 3,430 shares of Eledon Pharmaceuticals common stock.
Eledon Pharmaceuticals director Allan Kirk reported acquiring common shares through the vesting of equity awards. On January 10, 2026, 3,430 restricted stock units (RSUs) that had been granted on January 10, 2025 vested in full and were settled into 3,430 shares of Eledon Pharmaceuticals common stock on a one-for-one basis.
The RSU settlement was reported at a price of $0 per share, reflecting that no cash was paid in this conversion. Following the transaction, Allan Kirk beneficially owned 3,430 shares of common stock directly.
Eledon Pharmaceuticals director Keith Katkin reported the vesting and settlement of restricted stock units into common shares. On January 10, 2026, 8,575 restricted stock units converted into 8,575 shares of Eledon Pharmaceuticals common stock at a price of $0 per share, reflected as a transaction coded "M". These RSUs were originally granted on January 10, 2025 and vested 100% on January 10, 2026. Following the transaction, Katkin beneficially owned 8,575 shares of common stock directly.
Eledon Pharmaceuticals director June Lee reported the vesting and settlement of restricted stock units into common shares. On January 10, 2026, 3,430 restricted stock units converted into 3,430 shares of common stock at a price of $0 per share, leaving Lee with 3,430 common shares held directly after the transaction.
The footnote explains that these shares came from restricted stock units granted on January 10, 2025, which vested 100% on January 10, 2026 on a one-for-one basis into common stock. Following the conversion, the derivative position in these restricted stock units was reduced to zero.
Eledon Pharmaceuticals director reports RSU vesting and share settlement. Director James A. Robinson Jr. settled 3,430 restricted stock units (RSUs) into 3,430 shares of common stock on January 10, 2026, in a transaction coded "M" at a price of $0 per share. The RSUs were originally granted on January 10, 2025 and vested 100% on January 10, 2026.
Following this settlement, Robinson directly holds 3,430 shares of Eledon Pharmaceuticals common stock. The derivative position in the RSUs reported in this filing is now shown as 0 derivative securities beneficially owned, reflecting the full conversion into common shares.